Malaysia was the largest of BioNexus Gene Lab Corp’s 6 reported lines in fiscal 2025, at $5.83M — 79% of $7.42M.
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Malaysia | $8.22M | $7.46M | $5.83M |
| Maldives | $637.19K | $762.14K | $680.99K |
| Sri Lanka | $87.03K | $459.00K | $452.64K |
| Singapore | $244.40K | $572.03K | $240.76K |
| Indonesia | — | $138.30K | $114.87K |
| Bangladesh | $538.06K | $123.27K | $106.25K |
| Nigeria | $42.07K | — | — |
| Total | $9.77M | $9.51M | $7.42M |
In fiscal 2025, which ended December 31, 2025, the 6 regions BioNexus Gene Lab Corp reported in this breakdown added up to $7.42M. That was down 21.9% from $9.51M in fiscal 2024. Malaysia was the largest region, at $5.83M or 78.5% of the total, followed by Maldives ($680.99K, 9.2%) and Sri Lanka ($452.64K, 6.1%). Together, the two largest regions made up 87.7% of this total.
Compared with fiscal 2024, every sizeable region reported in both years shrank. Sri Lanka held up best, down 1.4% to $452.64K, while Singapore fell the most, down 57.9% to $240.76K.
Indonesia was first reported as a separate region in fiscal 2024. The table also keeps 1 region that BioNexus Gene Lab Corp no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2023 to 2025, as reported in BioNexus Gene Lab Corp's annual filings.
Trading Of Industrial Chemicals was the largest of BioNexus Gene Lab Corp’s 3 reported lines in fiscal 2025, at $7.41M — 99% of $7.44M.
| Timing of Transfer of Good or Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Trading Of Industrial Chemicals | $9.75M | $9.49M | $7.41M |
| Screening Services & Related Sales | $24.22K | $16.07K | $19.09K |
| Provision For Genomic Screening Services | — | $16.07K | $19.09K |
| Total | $9.77M | $9.53M | $7.44M |
In fiscal 2025, which ended December 31, 2025, the 3 revenue lines BioNexus Gene Lab Corp reported in this breakdown added up to $7.44M. That was down 21.9% from $9.53M in fiscal 2024. Trading Of Industrial Chemicals was the largest revenue line, at $7.41M or 99.5% of the total, followed by Screening Services & Related Sales ($19.09K, 0.3%) and Provision For Genomic Screening Services ($19.09K, 0.3%). Together, the two largest revenue lines made up 99.7% of this total.
Provision For Genomic Screening Services was first reported as a separate revenue line in fiscal 2024. This breakdown covers every fiscal year from 2023 to 2025, as reported in BioNexus Gene Lab Corp's annual filings.
Chemrex was the largest of BioNexus Gene Lab Corp’s 2 reported lines in fiscal 2022, at $10.83M — 99% of $10.93M.
| Related Party Transaction | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|
| Chemrex | $11.26M | $11.85M | $10.83M |
| Bionexus Malaysia | $134.10K | $1.52M | — |
| Mrna Scientific Malaysia | — | — | $95.82K |
| Total | $11.39M | $13.36M | $10.93M |
In fiscal 2022, which ended December 31, 2022, the 2 revenue lines BioNexus Gene Lab Corp reported in this breakdown added up to $10.93M. The revenue lines reported changed from fiscal 2021, so the total is not directly comparable with the $13.36M reported that year. Chemrex was the largest revenue line, at $10.83M or 99.1% of the total, followed by Mrna Scientific Malaysia ($95.82K, 0.9%).
Mrna Scientific Malaysia was first reported as a separate revenue line in fiscal 2022. The table also keeps 1 revenue line that BioNexus Gene Lab Corp no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2020 to 2022, as reported in BioNexus Gene Lab Corp's annual filings.
BioNexus Gene Lab Corp (BGLC) breaks its revenue down by region and revenue line. In fiscal 2025, its largest region was Malaysia, with $5.83M or 78.5% of the total, followed by Maldives at $680.99K (9.2%).
Malaysia was BioNexus Gene Lab Corp's largest region in fiscal 2025, with $5.83M in revenue, 78.5% of the $7.42M reported across its 6 regions.
Trading Of Industrial Chemicals was BioNexus Gene Lab Corp's largest revenue line in fiscal 2025, with $7.41M in revenue, 99.5% of the $7.44M reported across its 3 revenue lines.
Every figure is taken from BioNexus Gene Lab Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2023 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.